ADVM (Adverum Biotechnologies) ROCE % : -53.36% (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adverum Biotechnologies's annualized ROCE % for the quarter that ended in Sep. 2024 was -53.36%.

Adverum Biotechnologies ROCE % Historical Data

The historical data trend for Adverum Biotechnologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies ROCE % Chart

Adverum Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-33.76

-35.47

-33.21

-45.25

-58.46

Adverum Biotechnologies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-75.72	-66.22	-54.44	-34.98	-53.36

Adverum Biotechnologies ROCE % Calculation

Adverum Biotechnologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-123.991	/	( ( (308.372 - 32.246)	+	(173.01 - 24.914) )	/ 2 )
	=	-123.991	/	( (276.126	+	148.096)	/ 2 )
	=	-123.991	/	212.111
	=	-58.46 %

Adverum Biotechnologies's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-116.884	/	( ( (253.803 - 22.461)	+	(234.375 - 27.657) )	/ 2 )
	=	-116.884	/	( ( 231.342	+	206.718 )	/ 2 )
	=	-116.884	/	219.03
	=	-53.36 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Adverum Biotechnologies (NAS:ADVM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adverum Biotechnologies ROCE % Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0HA3:UK AVU0:Germany

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Executives

Lupher, Jr. Mark L.	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
James Paul Scopa	director	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi	officer: Chief Development Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein	officer: Chief Financial Officer	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar	officer: Chief Legal Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley	officer: Chief Scientific Officer	100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer	director, officer: CEO and Director	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman	officer: Chief Medical Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota	officer: Principal Accounting Officer	ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow	officer: SVP, Genl Counsel, Acting CFO	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza	officer: Chief Financial Officer	C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden	director	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210